TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07192471: A First-in-Human Study of KK2223 in Participants With Relapsed or Refractory T Cell Non-Hodgkin Lymphoma

Sponsor: Kyowa Kirin, Inc. · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 72 pts

Competing Trials Overlap

14 Active Trials

Excess Burn Exposure

$2,419,032

Rescue Site Savings

+$1,602,216

Unlock Full NCT07192471 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07192471 Rescue Dossier →